Patents by Inventor Jean-Denis Durand
Jean-Denis Durand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11369595Abstract: The present invention concerns a tryptophan metabolite chosen from kynurenic acid, anthranilic acid, quinolinic acid, picolinic acid, quinaldic acid and the mixtures of same or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt of same, for use as a drug intended for increasing and/or maintaining muscle mass and/or strength in a mammal, and in particular intended for treating and/or preventing muscle atrophy in mammals and/or for promoting muscle growth in mammals doing exercise and aiming to increase muscle mass and/or quality and/or strength, for preventing the appearance of symptoms of sarcopenia or for rehabilitation following muscle loss and/or for improving recovery time after an intense physical effort.Type: GrantFiled: September 5, 2017Date of Patent: June 28, 2022Assignee: METABRAIN RESEARCHInventors: Sophie N. Raynal, Annick Audet, Valérie Autier, Christine Charon, Jean-Denis Durand, Micheline Kergoat
-
Publication number: 20190247385Abstract: The present invention concerns a tryptophan metabolite chosen from kynurenic acid, anthranilic acid, quinolinic acid, picolinic acid, quinaldic acid and the mixtures of same or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt of same, for use as a drug intended for increasing and/or maintaining muscle mass and/or strength in a mammal, and in particular intended for treating and/or preventing muscle atrophy in mammals and/or for promoting muscle growth in mammals doing exercise and aiming to increase muscle mass and/or quality and/or strength, for preventing the appearance of symptoms of sarcopenia or for rehabilitation following muscle loss and/or for improving recovery time after an intense physical effort.Type: ApplicationFiled: September 5, 2017Publication date: August 15, 2019Applicant: METABRAIN RESEARCHInventors: Sophie N. Raynal, Annick Audet, Valérie Autier, Christine Charon, Jean-Denis Durand, Micheline Kergoat
-
Patent number: 10350184Abstract: This invention relates to oxime and alkoxy derivatives of the general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and/or prevention of muscle atrophy in mammals and/or for limiting muscular atrophy in mammals and/or to promote muscle growth in exercising mammals aimed at increasing muscle mass and quality, preventing the occurrence of symptoms of sarcopenia related to age or rehabilitation after a muscle loss, age-related muscle atrophy and/or the consequences of drug therapy and/or immobilization and/or cachexia.Type: GrantFiled: April 14, 2016Date of Patent: July 16, 2019Assignee: METABRAIN RESEARCHInventors: Sophie N. Raynal, Micheline R. Kergoat, Valerie Autier, Christine G. Charon, Jean-Denis Durand, Franck F. Lepifre, Annick M. Audet
-
Patent number: 10316056Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.Type: GrantFiled: April 9, 2018Date of Patent: June 11, 2019Assignees: BIOPHYTIS, SORBONNE UNVERSITÉInventors: René Lafont, Waly Dioh, Sophie Raynal, Stanislas Veillet, Franck Lepifre, Jean-Denis Durand
-
Publication number: 20180327444Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.Type: ApplicationFiled: April 9, 2018Publication date: November 15, 2018Inventors: RENÉ LAFONT, WALY DIOH, SOPHIE RAYNAL, STANISLAS VEILLET, FRANCK LEPIFRE, JEAN-DENIS DURAND
-
Publication number: 20180303780Abstract: This invention relates to a derivative of the general formula (I), as follows: or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and/or prevention of muscle atrophy in mammals and/or for limiting muscular atrophy in mammals and/or to promote muscle growth in exercising mammals aimed at increasing muscle mass and quality, preventing the occurrence of symptoms of sarcopenia related to age or rehabilitation after a muscle loss, age-related muscle atrophy and/or the consequences of drug therapy and/or immobilization and/or cachexia.Type: ApplicationFiled: April 14, 2016Publication date: October 25, 2018Inventors: Sophie N. RAYNAL, Micheline R. KERGOAT, Valerie AUTIER, Christine G. CHARON, Jean-Denis DURAND, Franck F. LEPIFRE, Annick M. AUDET
-
Patent number: 9938315Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.Type: GrantFiled: May 20, 2015Date of Patent: April 10, 2018Assignees: BIOPHYTIS, UNIVERSITÉ PARIS 6 PIERRE ET MARIE CURIEInventors: René Lafont, Waly Dioh, Sophie Raynal, Stanislas Veillet, Franck Lepifre, Jean-Denis Durand
-
Publication number: 20170226151Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.Type: ApplicationFiled: May 20, 2015Publication date: August 10, 2017Inventors: RENÉ LAFONT, WALY DIOH, SOPHIE RAYNAL, STANISLAS VEILLET, FRANCK LEPIFRE, JEAN-DENIS DURAND
-
Patent number: 9365584Abstract: The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases.Type: GrantFiled: December 28, 2010Date of Patent: June 14, 2016Assignee: PoxelInventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
-
Patent number: 9284329Abstract: Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies.Type: GrantFiled: June 28, 2013Date of Patent: March 15, 2016Assignee: POXELInventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
-
Publication number: 20150166566Abstract: Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies.Type: ApplicationFiled: June 28, 2013Publication date: June 18, 2015Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon
-
Publication number: 20130053401Abstract: The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases.Type: ApplicationFiled: December 28, 2010Publication date: February 28, 2013Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Sébastien Bolze, Franck Lepifre, Laurent Faveriel, Jean-Denis Durand, Christine Charon